Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.55 USD | -2.67% | -2.43% | -6.43% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.43% | 18.95M | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating